Essential Partners LLC Decreases Position in Regeneron Pharmaceuticals, Inc. $REGN

Essential Partners LLC reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 54.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 735 shares of the biopharmaceutical company’s stock after selling 872 shares during the period. Essential Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $568,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. Vestor Capital LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 482.5% in the 1st quarter. Vestor Capital LLC now owns 11,655 shares of the biopharmaceutical company’s stock valued at $9,005,000 after buying an additional 9,654 shares in the last quarter. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $26,000. Bank of America Corp DE lifted its position in Regeneron Pharmaceuticals by 2.8% in the first quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company’s stock valued at $919,120,000 after acquiring an additional 32,158 shares during the last quarter. Janus Henderson Group PLC lifted its position in Regeneron Pharmaceuticals by 1.7% in the first quarter. Janus Henderson Group PLC now owns 209,248 shares of the biopharmaceutical company’s stock valued at $161,637,000 after acquiring an additional 3,576 shares during the last quarter. Finally, Bull Harbor Capital LLC acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at $1,596,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by insiders.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Results exceeded expectations: Regeneron reported second-quarter revenue of $4.29 billion, up 16.7% year over year and above the roughly $3.82 billion consensus estimate. Non-GAAP EPS was $14.29 versus expectations of approximately $10.16, helping drive renewed investor interest. Regeneron Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: Key growth products performed well: Dupixent sales, recorded by partner Sanofi, rose 38% to a record $6.0 billion, while U.S. EYLEA HD sales increased 52% to a record $596 million. Libtayo sales also grew 30% to $489 million, demonstrating strength beyond the company’s legacy EYLEA franchise. Regeneron beats quarterly estimates on eczema drug strength, shares rise
• Positive Sentiment: Pipeline and strategic expansion: Management highlighted its broader development pipeline, while a collaboration with Telix Pharmaceuticals could expand Regeneron’s oncology presence through next-generation radiopharmaceutical therapies. Why Regeneron is up after mixed Q2 results and Telix oncology deal
• Neutral Sentiment: Dividend declared: Regeneron announced a quarterly dividend of $0.94 per share, payable August 31 to shareholders of record August 18. The approximately 0.5% yield provides limited income support but is unlikely to be a major valuation driver.
• Neutral Sentiment: Broader sector weakness: Healthcare stocks declined late in the session, creating a headwind for the group even as Regeneron benefited from its earnings release.
• Negative Sentiment: Fianlimab-Libtayo trial litigation: Multiple law firms publicized a securities class action alleging that Regeneron misrepresented the risks and protocol changes surrounding the failed Phase 3 melanoma trial. The allegations relate to investors who purchased shares from August 1, 2025, through May 15, 2026; the lead-plaintiff deadline is September 14, 2026. The lawsuit follows an earlier, severe market reaction to the trial failure and could add legal costs and reputational risk, although the claims have not been proven. Hagens Berman Regeneron securities class action alert

Analysts Set New Price Targets

Several equities analysts have issued reports on REGN shares. Morgan Stanley dropped their price objective on Regeneron Pharmaceuticals from $788.00 to $730.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 8th. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Cantor Fitzgerald dropped their price target on Regeneron Pharmaceuticals from $785.00 to $750.00 and set an “overweight” rating on the stock in a research note on Monday, July 6th. TD Cowen lifted their price target on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research report on Thursday, April 23rd. Finally, Royal Bank Of Canada reduced their price objective on Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating for the company in a research note on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $787.88.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $738.34 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $821.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The business has a 50 day simple moving average of $640.66 and a 200-day simple moving average of $711.35. The stock has a market capitalization of $78.06 billion, a PE ratio of 17.99, a price-to-earnings-growth ratio of 27.78 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the company earned $12.81 earnings per share. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 2.06 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.